Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Mark SullivanChief Legal Officer | Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 09/25 | 09/29 | 14,051 sh | $36.57 | $513,845.07 | −2.8% |
Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 09/25 | 09/29 | 3,377 sh | $36.57 | $123,496.89 | −0.8% | |
Matthew T. WileyChief Commercial Officer | Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 09/25 | 09/29 | 3,097 sh | $36.57 | $113,257.29 | −0.9% |
Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 09/25 | 09/29 | 31,550 sh | $36.57 | $1,153,783.5 | −1.4% | |
Daniel KarlinChief Medical Officer | Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 09/25 | 09/29 | 10,853 sh | $36.57 | $396,894.21 | −1.4% |
Mark SullivanChief Legal Officer | Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 06/25 | 06/26 | 13,008 sh | $45.03 | $585,750.24 | −3.9% |
Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 06/25 | 06/26 | 3,013 sh | $45.03 | $135,675.39 | −1.4% | |
Matthew T. WileyChief Commercial Officer | Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 06/25 | 06/26 | 2,867 sh | $45.03 | $129,101.01 | −1.6% |
Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 06/25 | 06/26 | 29,208 sh | $45.03 | $1,315,236.24 | −2.6% | |
Daniel KarlinChief Medical Officer | Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 06/25 | 06/26 | 10,035 sh | $45.03 | $451,876.05 | −2.0% |
Mark SullivanChief Legal Officer | Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 03/25 | 03/26 | 10,702 sh | $18.47 | $197,665.94 | −3.8% |
Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 03/25 | 03/26 | 24,431 sh | $18.47 | $451,240.57 | −3.1% | |
Daniel KarlinChief Medical Officer | Definium TherapeuticsDFTX | Open-market sale10b5-1 plan | 03/25 | 03/26 | 8,018 sh | $18.47 | $148,092.46 | −1.9% |
